UNSPSC 51422401: 11-deoxycortisol or cortexolone or cortodoxone

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WDT5SLP0HQ, chemically known as 17,21-dihydroxyprogesterone but generally known as 11-desoxy-17-hydroxycorticosterone, which bears US NIH Compound Identifier 9050. European Medicines Agency schedules Cortodoxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06810MIG. The term 11-DESOXY-17-HYDROXYCORTICOSTERONE is an International Non-Proprietary Name.

SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C(=O)CO.

UNSPSC 51422401 (11-deoxycortisol or cortexolone or cortodoxone) is a Commodity code that shows a sharp disconnect between its nominal pharmaceutical scope and the state and local work actually being solicited under it. Recent opportunities tagged to this code do not involve the steroid compounds the code names; instead, they cover naloxone procurement and therapeutic pharmacy program design. The code's abstract definition does not align with the concrete purchasing activity in the source material, suggesting either a tagging error in the underlying opportunity records or that the code is being misapplied to broader health-service categories. State and local health agencies — county health departments and state health and human services commissions — are the primary issuing bodies active under the code in recent months.

Activity is concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs for state employee and retiree health plans, with no formal response deadline specified as this was an exploratory information-gathering phase. The Seminole County solicitation specifies a two-year initial term with optional one-year renewal, fixed-fee pricing, and standard compliance requirements including E-Verify and drug-free workplace certification. Neither opportunity names an incumbent or specifies explicit disadvantaged-enterprise set-asides. Given the code mismatch, firms pursuing work in pharmaceutical supply, naloxone distribution, or state pharmacy benefit management should verify that opportunities are properly coded before investing pre-bid resources.